Eli Lilly and Company's venture capital efforts, primarily through Lilly Ventures, focus on investing in early to expansion-stage life sciences companies across biotechnology, medical devices, and diagnostics, aiming to foster innovation and provide strategic resources. Additionally, they have a Social Impact Venture Capital Portfolio dedicated to improving healthcare access for underserved communities and a new Biotech Ecosystem Venture Fund with Andreessen Horowitz to advance therapeutic platforms and cutting-edge health technologies.
Portfolio
12
Fund Size
—
Top Stage
Series B
Last 12 Mo
5
Stage Distribution
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Recludix Pharma | Unknown | — | Jan 2026 |
| Gate Bioscience | Series B | $65M | Nov 2025 |
| Trogenix | Series A | $80M | Oct 2025 |
| Dualitas Therapeutics, Inc. | Series A | $65M | Sep 2025 |
| Solu Therapeutics | Series A | $41M | Apr 2025 |
| ViaNautis Bio | Series A | $25M | Nov 2023 |
| Flare Therapeutics Inc. | Series B | $123M | Mar 2023 |
| PrescriberPoint | Seed | — | Jan 2023 |
| Arkuda Therapeutics | Series B | $64M | Feb 2022 |
| Foghorn Therapeutics | Series C | $80M | Dec 2021 |
| DTx Pharma | Series B | $100M | Mar 2021 |
| Seraxis | Series C | $40M | Feb 2021 |
Top Co-Investors
Alexandria Venture Investments3 shared
Versant Ventures2 shared
Access Biotechnology2 shared
Cormorant Asset Management2 shared
Surveyor Capital2 shared
Casdin Capital1 shared
Eventide Asset Management1 shared
Invus1 shared
Nextech Invest1 shared
Third Rock Ventures1 shared
Novartis Venture Fund1 shared
Pavilion Capital1 shared
BGF1 shared
UCB1 shared
Cystic Fibrosis Foundation1 shared
Origin Ventures1 shared
Forbion1 shared
GV (Google Ventures)1 shared
ARCH Venture Partners1 shared
Last updated: 3 March 2026